Teva Seeks To Bar FDA Approval Of Risperdal ANDAs

Law360, New York (September 15, 2008, 12:00 AM EDT) -- Teva Pharmaceuticals USA Inc. has asked a court to temporarily prohibit federal regulators from approving generic versions of the anti-psychotic drug Risperdal after an appeals court overturned a ruling granting the generics maker 180-day market exclusivity for the drug.

In a motion filed Monday in the U.S. District Court for the District of Columbia, Israel-based Teva sought to delay the impact of last week's appellate court ruling on its market share until it can conduct further discovery in the matter.

Teva wants the court to issue...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.